Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TH-302 + Bevacizumab for Glioblastoma Following Bevacizumab Failure
NCT02342379Phase 2Completed
- Sponsor
- UT Health San Antonio
- Start
- May 2015
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of evofosfamide in glioblastoma (GBM), sponsored by UT Health San Antonio. Primary endpoint: Number of Patients With Adverse Events at 4 months. Started May 2015; status: completed.
02
Drugs
evofosfamide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02342379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02342379.